Coegin Pharma AB Income Statement

Financials in millions SEK. Fiscal year is January - December.

Millions SEK. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	2020
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	2020
Operating Revenue	0.08	-	-	-	-	Upgrade
Other Revenue	0.29	-	-	-	-	Upgrade
Revenue	0.37	-	-	-	-	Upgrade
Cost of Revenue	0.85	0.02	0.02	-	-	Upgrade
Gross Profit	-0.48	-0.02	-0.02	-	-	Upgrade
Selling, General & Admin	16.9	20.29	25.21	34.94	31.91	Upgrade
Other Operating Expenses	0.05	0.01	-0.43	-2.97	-4.74	Upgrade
Operating Expenses	19.98	23.32	27.8	34.69	27.18	Upgrade
Operating Income	-20.45	-23.33	-27.82	-34.69	-27.18	Upgrade
Interest Expense	-0.02	-0.46	-0.05	-0.22	-	Upgrade
Interest & Investment Income	-	0	0.02	0.01	-	Upgrade
Earnings From Equity Investments	-	-0.05	-	-	-	Upgrade
Currency Exchange Gain (Loss)	-	0.06	-0.14	-0.33	0.04	Upgrade
Other Non Operating Income (Expenses)	-0	-	-	-	-	Upgrade
Pretax Income	-20.48	-23.78	-27.98	-35.24	-27.15	Upgrade
Income Tax Expense	0.02	-	-	-	-	Upgrade
Net Income	-20.5	-23.78	-27.98	-35.24	-27.15	Upgrade
Net Income to Common	-20.5	-23.78	-27.98	-35.24	-27.15	Upgrade
Shares Outstanding (Basic)	25	19	9	7	6	Upgrade
Shares Outstanding (Diluted)	25	19	9	7	6	Upgrade
Shares Change (YoY)	31.93%	105.53%	34.42%	15.36%	354.98%	Upgrade
EPS (Basic)	-0.82	-1.26	-3.04	-5.14	-4.59	Upgrade
EPS (Diluted)	-0.82	-1.26	-3.04	-5.14	-4.59	Upgrade
Gross Margin	-128.23%	-	-	-	-	Upgrade
Operating Margin	-5498.12%	-	-	-	-	Upgrade
Profit Margin	-5509.95%	-	-	-	-	Upgrade
EBITDA	-17.43	-20.32	-24.79	-31.97	-27.17	Upgrade
D&A For EBITDA	3.02	3.02	3.02	2.72	0.01	Upgrade
EBIT	-20.45	-23.33	-27.82	-34.69	-27.18	Upgrade
Revenue as Reported	0.37	0.06	0.57	3.13	4.76	Upgrade

Source: S&P Capital IQ. Standard template. Financial Sources.